Sandbox: Difference between revisions
No edit summary |
No edit summary |
||
| Line 24: | Line 24: | ||
*If patient responds orally load with 25-50mg | *If patient responds orally load with 25-50mg | ||
|| | || | ||
*Particularly useful when A-fib a/w exercise, after acute MI, or w/ thyrotoxicosis | *Particularly useful when A-fib a/w exercise, after acute [[MI]], or w/ [[thyrotoxicosis]] | ||
*Also long-term beta blocker improves patient survival whereas non-dihydropyridine calcium channel blockers may even worsen outcomes. Important to consider if a patient will most likely be started on a beta blocker upon discharge then strongly consider using the agent for | *Also long-term beta blocker improves patient survival whereas non-dihydropyridine calcium channel blockers may even worsen outcomes. Important to consider if a patient will most likely be started on a beta blocker upon discharge then strongly consider using the agent for rate control if they do not have any relative contraindications.<ref>Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999 Jun 12;353(9169):2001-7Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II–DAVIT II). Am J Cardiol. 1990 Oct 1;66(10):779-85</ref> | ||
|| | || | ||
*COPD | *[[COPD]] | ||
*Asthma | *[[Asthma]] | ||
*Decompensated heart failure | *[[Decompensated heart failure]] | ||
*Hypotension | *[[Hypotension]] | ||
|- | |- | ||
| [[Esmolol]]|| | | [[Esmolol]]|| | ||
| Line 52: | Line 52: | ||
*Consider as initial therapy for pts with LV dysfunction who: | *Consider as initial therapy for pts with LV dysfunction who: | ||
**Do not achieve rate control targets on beta blockers alone | **Do not achieve rate control targets on beta blockers alone | ||
**Cannot tolerate addition of or increased doses of beta blocker due to decompensated CHF | **Cannot tolerate addition of or increased doses of beta blocker due to decompensated [[CHF]] | ||
**Would have digoxin added anyway to improve | **Would have [[digoxin]] added anyway to improve [[CH]]F symptoms independent of A-fib | ||
*Consider as initial therapy in pts with severe hypotension | *Consider as initial therapy in pts with severe hypotension | ||
*Consider as 2nd agent in pts in whom IV BB or IV CCB has failed to control their rate | *Consider as 2nd agent in pts in whom IV BB or IV CCB has failed to control their rate | ||
| Line 63: | Line 63: | ||
|| | || | ||
*Consider for patients with decompensated heart failure or those with accessory pathways | *Consider for patients with decompensated heart failure or those with accessory pathways | ||
*2nd-line agent for chronic rate control when BBs and CCBs, alone, combined, or when used with digoxin, are ineffective | *2nd-line agent for chronic rate control when [[BBs]] and [[CCBs]], alone, combined, or when used with [[digoxin]], are ineffective | ||
|| | || | ||
|} | |} | ||
Revision as of 16:48, 27 February 2015
| Medication | Dose | Comments | Contraindications |
| Calcium-Channel Blockers | |||
| Diltiazem |
|
| |
| Beta-Blockers | |||
| Metoprolol |
|
|
|
| Esmolol |
|
|
|
| Other | |||
| Digoxin | |||
|
|
||
| Amiodarone |
|
- ↑ Short PM, Lipworth SI, Elder DH, Schembri S, Lipworth BJ. Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ. 2011 May 10;342:d2549
- ↑ Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999 Jun 12;353(9169):2001-7Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II–DAVIT II). Am J Cardiol. 1990 Oct 1;66(10):779-85
- ↑ Khan IA et al. Amiodarone for pharmacological cardioversion of recent-onset atrial fibrillation. Int J Cardiol. 2003 Jun;89(2-3):239-48.
